Esclerose múltipla: tratamento farmacológico e revisão de literatura

Paolo Ruggero Errante; Renato Ribeiro Nogueira Ferraz; Francisco Sandro Menezes Rodrigues

Esclerose múltipla: tratamento farmacológico e revisão de literatura

Paolo Ruggero Errante, Renato Ribeiro Nogueira Ferraz, Francisco Sandro Menezes Rodrigues

Resumo

Introdução: A esclerose múltipla (EM) é uma doença autoimune desmielinizante caracterizada por défices neurológicos disseminados no tempo e no espaço com repercussões graves sobre as atividades diárias de vida. As terapêuticas de primeira linha para o tratamento de EM incluem apresentações farmacológicas do interferon beta-1b, interferon beta-1a e acetato de glatirâmero. O tratamento de segunda utiliza o Natalizumab e Fingolimod, e o tratamento de terceira linha utiliza a Mitoxantrona. Método: A revisão foi realizada por levantamento bibliográfico de banco de dados obtidos através de pesquisa direta, LILACS, MEDLINE e capítulos de livros. Resultados: A revisão literária demonstra a importância do diagnóstico e tratamento precoce da EM, evitando o surgimento de novos surtos ou novos padrões clínicos da doença. Conclusão: A EM é uma doença neurodegenerativa progressivamente incapacitante. As terapêuticas modificadoras da doença são parcialmente eficazes na prevenção da destruição axonal, mas são praticamente destituídas de eficácia, na prevenção do tratamento da degeneração, na fase progressiva.

Palavras-chave: Esclerose múltipla. Enfermidade autoimune. Neurologia. Desmielinização. Terapia modificadora da doença.

Texto completo:

PDF

Referências

Alonso A, Hernán M. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008; 71(2):129-35.

Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA,Haines JL, Hauser SL; Multiple Sclerosis Genetics Group. HLA-DR2 Dose Effect on Susceptibility to Multiple Sclerosis and Influence on Disease Course. Am J Hum Genet. 2003; 72(3):710-6.

Ben-Zacharia AB. Therapeutics for Multiple Sclerosis Symptoms. Mount Sinai Journal of Medicine. 2011;78:176-91.

Bloomgren G, Richman S, Hotermans C, Subramanyam, Meena Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012; 366(20):1870-80.

Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, Sandrock A, Bloomgren G. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011; 70(5):742-750.

Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):402-15.

Coles AJ, Compston A. Multiple sclerosis. Medicine. 2004; 32(11):87-92.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology. 2012; 78(14):1069-78.

Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol. 2012; 142(1):2-8.

Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, Hartung H, Seeldrayers P, Sørensen PS, Rovaris M, Martinelli V, Hommes OR. Early Treatmentof Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001; 357:1576-82.

Comi G, Filippi M, Woìinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic ressonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001b; 49:290-7.

Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca M, Filippi M; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012; 366(11):1000-9.

Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. N Engl J Med. 2011; 365:1293-303.

Compston A. The pathogenesis and basis for treatment in multiple sclerosis. Clinical neurology and neurosurgery. 2004; 106(3):246-8.

Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372:1502-17.

Connor PWO. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011; 76(22):1858-65.

Daroff R, Fenichel G, Jankovic J, Mazziotta JC. Bradley’s Neurology in Clinical Practice. 6th ed. Elsevier Saunders; 2012.

Derfuss T, Kuhle J, Lindberg R, Kappos L. Natalizumab therapy for multiple sclerosis. Semin Neurol. 2013; 33(1):26-36.

Elian M, Nightingale S, Dean G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies. J Neurol Neurosurg Psychiatry. 1990; 53:906-11.

Fernandez O, Arroyo-Gonzalez R, Rodriguez-Antiguedad A, Garcia-Merino JA, Comabella M, Villar LM, Izquierdo G, Tintore M, Oreja-Guevara C, Alvarez-Cermeno JC, Meca-Lallana JE, Prieto JM, Ramio-Torrenta L, Martinez-Yelamos S, Montalban X. Biomarcadores en esclerosis múltiple. Rev Neurol. 2013; 56 (7): 375-390.

Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller DH. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008; 131:808-17.

Fuhr P, Kappos L. Evoked potentials for evaluation of multiple sclerosis. Clinical Neurophysiology. 2001; 112(12):2185-9.

Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Sarda SP, Zhang R, Viglietta V, Havrdova E. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clin Ther. 2015;37(11):2543-51.

Gobbi C, Meier DS, Cotton F, Sintzel M, Leppert D, Guttmann CR, Zecca C. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol. 2013; 13:101.

Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE,Subramanyam M. Anti-JC virus antibodies: implica¬tions for PML risk stratification. Ann Neurol. 2010; 68(3):295-303.

Hartung HP, Vermersch P, Olsson T. Principles of a new treatment algorithm in multiple sclerosis. Expert Rev Neurother. 2011; 11(3):351-62.

Hartung H-P, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002; 360:2018-25.

Irani DN. Immunological mechanisms in multiple sclerosis. Clinical and Applied Immunol Rev. 2005; 5(4):257-69.

Johnson KP. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Therapeutics and Clinical Risk Management. 2010; 6:153-72.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. N Engl J Med. 2010; 362(5):387-401.

Kappos L, Polman C, Freedman M, Edan G, Hartung H, Miller D, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006; 67(7):1242-9.

Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW,Sørensen PS, King J. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011; 10(8):745-58.

Khatri B, Barkhof F, Comi G, Hartung H-P, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011; 10(6):520-9.

Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011; 10(11):1026-34.

Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002; 125:2202-12.

Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD. Studies on natural history of multiple sclerosis. Acta Neurol Scandinav. 1968; 44:467-494.

Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. New Engl J Med. 2009; 361(11):1081-7.

Link H, Huang Y-M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. Journal of neuroimmunology. 2006; 180:17-28.

Lublin F, Reingold S. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996; 46(4):907-11.

Lycke J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord. 2015;8(6):274-93.

Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Neurology. 2004; 3:709-18.

Mehling M, Kappos L, Derfuss T. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci Rep. 2011; 11(5):492-7.

Menge T, Weber MS, Hemmer B, Kieseier BC, Büdingen H-C, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stüve O. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs. 2008; 68(17):2445-68.

Mirshafiey A, Kianiaslani, M. Autoantigens and Autoantibodies in Multiple Sclerosis. Iran J Allergy Asthma Immunol. 2013; 12(4):292-303.

Neuhaus O, Kieseier BC, Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacology & Therapeutics. 2006; 109:198-209.

Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012; 122(4):1180-8.

Owens GP, Gilden D, Burgoon MP, Yu X, Bennett JL. Viruses and multiple sclerosis. Neuroscientist. 2011; 17(6):659-76.

Pierrot-Deseilligny C, Souberbielle J-C. Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain. 2010; 133:1869-88.

Patti F, Pappalardo A, Florio C, Politi G, Fiorilla T, Reggio E, Reggio A. Effects of interferon beta-1a and beta-1b over time: 6-year results of an observational head-to-head study. Acta Neurol Scand. 2006; 113(4):241-7.

Pawate S, Bagnato F. Newer agents in the treatment of multiple sclerosis. Neurologist. 2015; 19(4):104-17.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA,Sandrock AW; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):899-910.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P,Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292-302.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA,Sandrock AW, AFFIRM Investigators. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N Engl J Med. 2006; 354:899-910.

PRISMS (Prevension of Relapses and Disability by Interferon B-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised study of interferon B-1a in relapsing/remitting multiple sclerosis. Lancet. 1993; 352:1498-504.

PRISMS (Prevention of Relapses and Disability by Interferon B-1a Subcutaneously in Multiple Sclerosis) Study Group and the Univeristy of British Cloumbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-B-1a in relapsing MS. Neurology. 2001; 56(12):1-13.

Pulicken M, Gordon-Lipkin E, Balcer LJ, Frohman E, Cutter G, Calabresi PA. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 2007; 69: 2085-92.

Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, Diez-Tejedor E. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. J Clin Immunol. 2011; 31(4):623-31.

Río J, Comabella M, Montalban X. Multiple sclerosis: current treatment algorithms. Curr Opin Neurol. 2011; 24(3):230-7.

Rudick RA, Panzarra MA. Natalizumab for the treatment of relapsing multiple sclerosis. Biologics: Targets & Therapy. 2008; 2(2):1-11.

Rommer PS, Patejdl R, Winkelmann A, Benecke R, Zettl UK. Rituximab for secondary progressive multiple sclerosis: a case series. CNS Drugs. 2011 Jul; 25(7):607-13.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):911-23.

Sahraian MA, Eshaghi A. Role of MRI in diagnosis and treatment of multiple sclerosis. Clin Neurol Neurosurg. 2010; 112(7):609-15.

Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010; 133:1914-29.

Soelberg SP, Drulovic J, Havrdova E, Lisby S, Graff O, Shackelford S. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing remitting multiple sclerosis (RRMS)-24-week results of a phase II study. Presented at: ECTRIMS; October 13-16, 2010; Gothenburg, Sweden. P136.

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology. 1993; 43:655-61.

Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2016; 23 Suppl 1:18-27.

Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH, Polman CH, Stevenson VL, McDonald WI. Diagnostic criteria for primary progressive multiple sclerosis: A position paper. Ann Neurol. 2000; 47(6):831-5.

Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012; 78(22):1736-1742.

Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol. 2005; 58:383-91.

Vollmer T. The natural history of relapses in multiple sclerosis. J Neurological Sciences. 2007; 256 Suppl: S5-13.

Walther EU, Hohfeld R. Multiple sclerosis side effects of interferon beta therapy and their management. Neurology. 1999; 53(8):1-10.

Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D; PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007; 61(1):14–24.

Zhang X, Markovic-Plese S. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Clinical Neurology and Neurosurgery. 2010; 112(7):641-5.

Zuvich RL, Mccauley JL, Pericak-vance MA, Haines JL. Genetics and pathogenesis of multiple sclerosis. Seminars in Immunology. 2009; 21:328-33.

Apontamentos

Não há apontamentos.

Direitos autorais 2016 Revista UNILUS Ensino e Pesquisa - RUEP

ISSN (impresso): 1807-8850
ISSN (eletrônico): 2318-2083

Periodicidade: Trimestral

Primeiro trimestre, jan./mar., data para publicação da edição - 30 de junho
Segundo trimestre, abr./jun., data para publicação da edição - 30 de setembro
Terceiro trimestre, jul./set., data para publicação da edição - 31 de dezembro
Quarto trimestre, out./dez., data para publicação da edição - 31 de março

Este obra está licenciado com uma Licença Creative Commons Atribuição-NãoComercial-SemDerivações 4.0 Internacional.